written on 19.03.2018

Lithuania Pharma Report 2018


Despite a tiny domestic market size, the Lithuanian life sciences sector is full of hidden surprises. Comprising four percent of the nation’s entire GDP, with one percent accounted for by a burgeoning biotechnology sector, Lithuania can draw on a strong science R&D infrastructure and a talented domestic labor pool.


The multinational affiliate leaders, heads of significant local players, key opinion leaders, government officials, and regulators featured in this report unpack these topics, along with a range of others including the country’s outstanding potential in clinical trials, the possibilities of acting as a biotech hub for the Baltics, and how companies are drawing on Lithuania’s heritage as one of the world’s leading manufacturers of lasers.

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here